Goutham Sunny

So now even taxanes supply is under threat. If the authorities can’t ensure that stocks of non expensive essential life saving cancer drugs are restored, request them to atleast issue an official legal order that absolves medical oncologists from the legal liability of inferior treatments and outcomes thanks to national shortage of these drugs, coz while we would very much like saving lives, when that is not facilitated by the Government and the global situation, we would very much like to atleast save our @$$! @MoHFW_INDIA @PMOIndia @JPNadda

In oncology we say one size doesn’t fit all, but if there are any drugs that work in almost all cancers, they have to be platinum drugs especially Cisplatin and Carboplatin. The simplest, effective and cheapest drugs that have no replacement in several cancers are out of stock in most hospitals in India, leaving patients and families to suffer with no treatments even in curable cancers. The global supply chain has been massively impacted, so are the import rates and manufacturing rates. While capping prices of drugs is a welcome move, flexibility that is reviewed dynamically is the need of the hour, a 50% rise in capped price of a 200 rupees drug that is life saving should be accommodated as the cost of lives lost is going to be much more. Request @narendramodi @PMOIndia @JPNadda @MoHFW_INDIA @AmitShahOffice to resolve the situation ASAP

This is a global issue for both Cisplatin and carboplatin .. @ChandrakanthMv needs to be highlighted … affecting so many pts @AyushmanNHA @CancerGridIndia @cspramesh @ASCO @DrSanjayPopat @myESMO … not an expensive drug so industry not bothered. @PMOIndia @JPNadda @ICMRDELHI @jrgralow @drkiwicj

Reviewing 1L options in advanced #HCC Atezo Bev still has the strongest signal and longest followup - across multiple subsets. ✅ AFP>400 ✅ Vp4 portal invasion ✅ Viral HCC ❓MAFLD ❓ Fibrolamellar TKIs with signals - Sora, Lenva, Cabo, Regora @OncoDailyGI @oncodaily #cancer

One of the most notable studies from #AACR26: Daraxonrasib + gem/nab-paclitaxel shows a strong early signal in 1L mPDAC. ORR 58% DCR 90% 6-month PFS 84%!! Things are finally moving in pancreatic cancer👇 aacrjournals.org/cancerres/arti…

Never forget this. Time is finite... Family always comes first. Courtesy @jenna_taglienti

Excited to share our new publication in Expert Opinion on Investigational Drugs: We discuss the role of CDK8/19 in AML transcription and early clinical data on romaciclib, including promising combinations with venetoclax in relapsed/refractory disease. tandfonline.com/doi/full/10.10…

Let's review the mech of Gonadotoxicity in #lymphoma Rx - ROS+direct damage ❌ Worst culprits - Alkylators - Procarbazine & cyclophos 👀 Jury's out on long term data - relatively safe - BV, Nivo, Pembro ⚠️ Teratogenicity - Etopo, Len #medtwitter #oncology #cancer #fertility

Let's review a few important uncommon mutations in #nsclc #lung #cancer MET, RET, KRAS, HER2, BRAF, HER2 Watch out for edema, HTN, pneumonitis with the MET/RET mTKIs! #lcsm #medtwitter #onctwitter (Slide 2 courtesy Dr Sumit, Shillong)

🧬✨ Just published: ESMO Guidelines 2026 in mCRC 📊 Molecular-driven algorithm consolidated 🧪 Mandatory profiling → RAS/BRAF, MSI, HER2 ±NGS 🎯 1L by biology → MSI-H: ICI | RAS wt left: anti-EGFR 💊 3L+ → FTD/TPI + BEV preferred 💥 Precision + sequencing redefine SoC 🔗 annalsofoncology.org/action/showPdf… @OncoAlert

Algorithm for Systemic Therapy in Early HR+/HER2- Breast Cancer (Recommendations in gray areas reflect my own clinical judgment— eg. olaparib and CDK4/6 sequence)

Algorithm for Systemic Therapy in Early TNBC (Based on NCCN and ESMO guidelines; recommendations in gray areas reflect the St. Gallen 2025 consensus and, in part, my own clinical judgment)

Grades of #chemotherapy response across tumors Higher is better in - Osteosarcoma Huvos, Ovarian CRS, Miller Payne Breast, Dvorak Rectum Lower is better in - Ryan CAP/Mandard/Becker GI malignancies, #RCB in breast #onctwitter #oncology #cancer #medtwitter #pathology

@DarwinAnil @todrashish @OffCMCVellore @JSMO_official Congratulations Anil! Three cheers to the silver and blue! Great recognition for dept of medical oncology and @OffCMCVellore

Honored to receive the Rising Star in Asia Award at JSMO 2026. I express my heartfelt gratitude to my mentor, @todrashish, for his constant guidance, also grateful to @OffCMCVellore for providing the opportunities that made this possible. @JSMO_official #JSMORISA2026

1/n Setidegrasib the first-in-human, first-in-class, KRAS G12D-targeted protein degrader #TPD Our KRAS G12D degrader study is now published in the New England Journal of Medicine @NEJM nejm.org/doi/full/10.10… A new way to target KRAS G12D - one of the most common oncogenic drivers across cancers.

💉 Pegfilgrastim timing matters 📊 Phase III RCT (breast cancer) ⏱️ 72h vs 24–48h post-CT 📉 Bone pain (AUC): 6.05 vs 12.7–14.2 🔥 📉 Severe pain: 22.6% vs ~60% ⚖️ No ↑ neutropenia or FN 💡 Delaying to 72h may reduce toxicity without compromising efficacy 🔗 doi.org/10.7326/ANNALS… @OncoAlert

Revising #IMWG multiple #myeloma response criteria Do you regularly do paired serum & urine electrophoresis/immunofixation assays? Or only serum? . . #hemonc #heme #oncology #cancer

@drmpk91 @Arvind_RadOnc @LancetRH_SEAsia @OffCMCVellore @todrashish @ajoyojohn @jtgeorgy @HK_DMonc @DarwinAnil Congratulations!!

Excited to share that our phase 2 trial #NeoLOCUS is now out in @LancetRH_SEAsia! A collective effort from the Head & Neck team @OffCMCVellore led by @todrashish We report R0 rates, ORR, safety, survival outcomes, tumor immune microenvironment change🧵👇 thelancet.com/journals/lanse…

Let's review #TNT Total Neoadjuvant Treatment and Organ Preservation in #Rectal #Cancers. 1. PRODIGE23 - Induction CT + CRT 2. PROSPECT - No RT & Mid/upper only 3. OPRA - Induction CRT CT Ph2 4. OPERA - Contact Brachy Boost 5. MORPHEUS - HDR BT boost #crcsm #Oncology